Phase III Study on the Effectiveness of OSAG 101 (Theraloc) [nimotuzumab] in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents

Trial Profile

Phase III Study on the Effectiveness of OSAG 101 (Theraloc) [nimotuzumab] in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Glioma
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncoscience
  • Most Recent Events

    • 29 Oct 2009 YM Biosciences announced in a media release, that updated results were presented by Oncoscience AG, at the 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP) held in Sao Paulo, Brazil from October 5th-9th, 2009.
    • 09 Oct 2009 Oncoscience presents results for the first time at the World's Convention for Pediatric Oncology.
    • 30 May 2008 Tolerability results presented at 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top